1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
    Meeting Abstract

    Kopetz, S.; Murphy, D. A.; Pu, J.; Yaeger, R.; Ciardiello, F.; Desai, J.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Alkuzweny, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
    Meeting Abstract

    Schmid, P.; Cortés, J.; Marmé, F.; Rugo, H. S.; Tolaney, S. M.; Oliveira, M.; Loirat, D.; Jhaveri, K.; Yoon, O. K.; Motwani, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Meeting Abstract

    Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)
    Meeting Abstract

    Kasper, S.; Segal, N. H.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; Amirouchene Angelozzi, N.; Amirouchene da Silva, A. P.; St-Pierre, A.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors
    Meeting Abstract

    Friedman, C.; Swanton, C.; Spigel, D.; Bose, R.; Burris, H.; Yu, W.; Wang, Y.; Malato, J.; Price, R.; Darbonne, W.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Marra, A.; Gazzo, A.; Gupta, A.; Selenica, P.; Da Silva, E. M.; Pareja, F.; Pei, X.; Zhu, Y.; Razavi, P.; Safonov, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers
    Meeting Abstract

    Marra, A.; Goldfinger, M.; Millar, E.; Hanna, M.; Rothrock, B.; Lee, M.; Wang, Y.; van Eck, A.; Tydlitatova, L. T.; Sue, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications
    Meeting Abstract

    Borad, M.; Javle, M.; Shaib, W. L.; Mody, K.; Bergamo, F.; Harris, W. P.; Damjanov, N.; Macarulla, T.; Brandi, G.; Masi, G.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Meeting Abstract

    Yoo, C.; Kim, K. P.; Kim, I.; Kang, M. J.; Cheon, J.; Kang, B. W.; Ryu, H.; Jeong, J.; Lee, J. S.; Kim, K. W.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Neutrophil phenotypes and functions in cancer: A consensus statement
    Review

    Quail, D. F.; Amulic, B.; Aziz, M.; Barnes, B. J.; Eruslanov, E.; Fridlender, Z. G.; Goodridge, H. S.; Granot, Z.; Hidalgo, A.; Huttenlocher, A.; more...
    Journal of Experimental Medicine (2022)

    Fulltext@MSK | Save